Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

References

• IDF Clinical Guidelines Task ForceGlobal guideline for type 2 diabetes: recommendations for standard, comprehensive and minimal careDiabet Med20062357959316759299
   PubMed Web of Science ®Google Scholar
• UKPDS GroupIntensive blood-glucose control with sulphonylureas or inslin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• ShichiriMKishikawaHOhkuboYLong-term results of the Kumamoto Study on Optimal Diabetes Control in type 2 diabetic patientsDiabetes Care200023B21B2910860187
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• CurrieCJPooleCDGaleEAThe influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia200972 (Epub ahead of print)
   Web of Science ®Google Scholar
• WhitmerRAKarterAJYaffeKQuesenberryCPJrSelbyJVHypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitusJAMA20093011565157219366776
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med20083582560257218539916
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetesN Engl J Med20083582545255918539917
   PubMed Web of Science ®Google Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1cDiabetes Care20032688188512610053
   PubMed Web of Science ®Google Scholar
• CerielloAHanefeldMLeiterLPostprandial glucose regulation and diabetic complicationsArch Intern Med20041642090209515505121
   PubMed Web of Science ®Google Scholar
• RazIWilsonPWFStrojekKEffects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trialDiabetes Care20093238138619246588
   PubMed Web of Science ®Google Scholar
• La BarreJSur les possibilities d’un traitement du diabète par l’incrétineBull Acad R Med Belg193212620634
   Google Scholar
• ElrickHStimmlerLHladCJAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• McIntyreNHoldsworthCDTurnerDANew interpretation of oral glucose toleranceLancet1964II202114149200
   PubMed Web of Science ®Google Scholar
• BrownJCMuttVPedersonRAFurther purification of polypeptide demonstrating enterogastrone activityJ Physiol197020957645499047
   PubMed Web of Science ®Google Scholar
• SchmidtWESiegelEFCreutzfeldtWGlucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic isletsDiabetologia1985287047073905480
   PubMed Web of Science ®Google Scholar
• NauckMAHombergerESiegelEGIncretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responsesJ Clin Endocrinol Metab1986634924983522621
   PubMed Web of Science ®Google Scholar
• NauckMAStockmannFEbertRCreutzfeldtWReduced incretin effect in type 2 (non-insulin-dependent) diabetesDiabetologia19862946523514343
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTMadsbadSHolstJJDefective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patientsDiabetologia2002451111111912189441
   PubMed Web of Science ®Google Scholar
• KjemsLLHolstJJVolundAMadsbadSThe influence of GLP-1 on glucose-stimulated insulin secretion effects on beta-cell sensitivity in type 2 and non-diabetic subjectsDiabetes20035238038612540611
   PubMed Web of Science ®Google Scholar
• HøjbergPVVilsbøllTRabølRFour weeks of nearnormalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetesDiabetologia20095219920719037628
   PubMed Web of Science ®Google Scholar
• DeaconCFNauckMAToft-NielsenMPridalLWillmsBHolstJJBoth subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjectsDiabetes199544112611317657039
   PubMed Web of Science ®Google Scholar
• KreymannBWilliamsGGhateiMABloomSRGlucagon-like peptide 1 7–36 a physiological incretin in manLancet19872130013042890903
   PubMed Web of Science ®Google Scholar
• O’DonovanDGDoranSFeinle-BissetCEffect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetesJ Clin Endocrinol Metab2004893431341515240627
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMBehleKEffects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive function, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteersJ Clin Endocrinol Metab2002871239124611889194
   PubMed Web of Science ®Google Scholar
• ScrocchiLABrownTJMaCluskyNGlucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor geneNat Med19962125412588898756
   PubMed Web of Science ®Google Scholar
• TsengCCZhangXYWolfeMMEffect of GIP and GLP-1 antagonists on insulin release in the ratAm J Physiol Endocrinol Metab1999276E1049E1054
   Web of Science ®Google Scholar
• ImeryuzNYeganBCBozkurtACoskunTVillanueva-PenacarriloMLUlusonNBGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanismsAm J Physiol Gastrointest Liver Physiol1997273G920G927
   PubMed Web of Science ®Google Scholar
• SchirraJSturmKLeichtPArnoldRGokeBKatschinskiMExendin (9–39) amide is an antagonist of glucagon-like peptide-1 (7–36) amide in humansJ Clin Invest1998101142114309525985
   PubMed Web of Science ®Google Scholar
• EdwardsCMToddJFMahmoudiMGlucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39Diabetes1999486939892226
   PubMed Web of Science ®Google Scholar
• SchirraJNicolausMRoggelPEndogenous glucagon-like peptide 1 controls endocrine pancreatic secretin and antro-pyloroduodenal motility in humansGut20065524325115985560
   PubMed Web of Science ®Google Scholar
• HorowitzMEdelbroekMAWishartJMRelationship between oral glucose tolerance and gastric emptying in normal healthy subjectsDiabetologia1993368578628405758
   PubMed Web of Science ®Google Scholar
• JonesKLHorowitzMCarneyBJGastric emptying in early non-insulin diabetes mellitusJ Nucl Med199637164316488862300
   PubMed Web of Science ®Google Scholar
• MourotJThouvenotPCouetCAntoineJMKrobickaADebryGRelationship between the rate of gastric emptying and glucose and insulin responses to starchy foods in young healthy adultsAm J Clin Nutr198848103510403048076
   PubMed Web of Science ®Google Scholar
• O’DonovanDHorowitzMRussoAEffects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetesDiabetologia2004472208221415662558
   PubMed Web of Science ®Google Scholar
• PerfettiRMerkelPGlucagon-like peptide-1: a major regulator of pancreatic beta-cell functionEur J Endocrinol200014371777511124853
   PubMed Web of Science ®Google Scholar
• DruckerDJPhillippeJMojsovSChickWLHaenerJFGlucagon-like peptide 1 stimulates gene expression and increases cyclic AMP level in a rat islet cell lineProc Natl Acad Sci U S A198784343434383033647
   PubMed Web of Science ®Google Scholar
• FarillaLBulottaAHirshbergBGlucagon-like peptide-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human isletsEndocrinology20031445149518812960095
   PubMed Web of Science ®Google Scholar
• LiLEl-KholyWRhodesCJBrubakerPLGlucagon-like peptide-1 protectsbeta cells from cytokine-induced apoptosis and necrosis: role of protein kinase BDiabetologia2005481339134915902400
   PubMed Web of Science ®Google Scholar
• Van DijkGLindskogSHolstJJSteffensABAhrenBEffects of glucagon-like peptide-I on glucose turnover in ratsAm J Physiol Endocrinol Metab1996270E1015E1021
   Web of Science ®Google Scholar
• ChelikaniPKHaverACReidelbergerRDIntravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in ratsAm J Physiol Regul Integr Comp Physiol1997288R1695R170615718384
   PubMed Web of Science ®Google Scholar
• RachmanJGribbleFMBarrowBALevyJCBuchananKDTurnerRCNormalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 7–36 amide in patients with NIDDMDiabetes199645152415308866556
   PubMed Web of Science ®Google Scholar
• Juntti-BerggrenLPigonJKarpeFThe antidiabetogenic effect of GLP-1 is maintained during a 7-day period and improves diabetic dyslipoproteinemia in NIDDM patientsDiabetes Care199619120012068908380
   PubMed Web of Science ®Google Scholar
• WillmsBWernerJHolstJJOrskovCCreutzfeldtWNauckMAGastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-7–36 amide in type 2 (noninsulin-dependent) diabetic patientsJ Clin Endocrinol Metab1996813273328550773
   PubMed Web of Science ®Google Scholar
• LittleTJPilichiewiczANRussoAEffects of intravenous GLP-1 on gastric emptying and intragastric distribution in healthy subjects – relationships with postprandial glycemic and insulinemic responsesJ Clin Endocrinol Metab2006911916192316492694
   PubMed Web of Science ®Google Scholar
• MeneillyGSGreigNTildesleyHHabenerJFEganJMElahiDEffects of 3 months of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetesDiabetes Care2003262835284114514588
   PubMed Web of Science ®Google Scholar
• ZanderMMadsbadSMadsenJLHolstJJEffect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group studyLancet200235982483011897280
   PubMed Web of Science ®Google Scholar
• NikolaidisLAMankadSSokosGGEffects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusionCirculation200410996296514981009
   PubMed Web of Science ®Google Scholar
• SokosGGNikolaidisLAMankadSElahiDShannonRPGlucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failureJ Card Fail20061269469917174230
   PubMed Web of Science ®Google Scholar
• SokosGGBolokogluHGermanJEffect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass graftingAm J Cardiol200710082482917719327
   PubMed Web of Science ®Google Scholar
• MüssigKOncuALindauerPEffects of intravenous glucagon-like peptide 1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetesAm J Cardiol200810264664718721530
   PubMed Web of Science ®Google Scholar
• NystromTGutniakMKZhangQEffects of glucagon-likep peptide 1 on endothelial function in type 2 diabetes patients with stable coronary artery diseaseAm J Physiol Endocrinol Metab2004287E1209E121515353407
   PubMed Web of Science ®Google Scholar
• BasuACharkoudianNSchrageWRizzaRABasuRJoynerMJBeneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepirideAm J Physiol Endocrinol Metab2007293E1289E129517711996
   PubMed Web of Science ®Google Scholar
• BanKNoyan-AshrafMHHoeferJCardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and-independent pathwaysCirculation20081172340235018427132
   PubMed Web of Science ®Google Scholar
• EngJKleinmanWASinghLSinghGRaufmanJPIsolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreasJ Biol Chem199226741084115
   Google Scholar
• ThorensBPorretABuhlerLDengSPMorelPWidmannCCloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin (9–39) an antagonist of the receptorDiabetes19934216786828405712
   PubMed Web of Science ®Google Scholar
• KoltermanOGBuseJBFinemanMSGainesEHeintzSSynthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetesJ Clin Endocrinol Metab2003883082308912843147
   PubMed Web of Science ®Google Scholar
• LinnebjergHParkSKotharePAEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetesRegul Pept200815112312918675854
   PubMedGoogle Scholar
• CvetkovicRSPloskerGLExenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea)Drugs20076793595417428109
   PubMed Web of Science ®Google Scholar
• NelsonPPoonTGuanXSchnabelCWintleMFinemanMThe incretin mimetic exenatide as a monotherapy in patients with type 2 diabetesDiabetes Technol Ther2007931732617705687
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care2005281092110015855572
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care2004272628263515504997
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care2005281083109115855571
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA20072585258917579226
   PubMed Web of Science ®Google Scholar
• BlondeLKleinEJHanJInterim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes Obes Metab2006843644716776751
   PubMed Web of Science ®Google Scholar
• ZinmanBHoogwerfBJDuranGSThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetesAnn Intern Med200714647748517404349
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRGExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Int Med200514355956916230722
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period crossover non-inferiority trialClin Ther2007292333234818158075
   PubMed Web of Science ®Google Scholar
• NauckMADuranSKimDA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia20075025926717160407
   PubMed Web of Science ®Google Scholar
• KimDMacConnellLZhuangDEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care2007301487149317353504
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKDURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet20083721240125018782641
   PubMed Web of Science ®Google Scholar
• KnudsenLBKnudsenSMWilkemMPlasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacyDiabetes2003A321A322
   PubMed Web of Science ®Google Scholar
• KnudsenLBNielsenPFHuusfeldtPOThe pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menDiabetologia20024519520211935150
   PubMed Web of Science ®Google Scholar
• VilsbollTZdravokovicMLe-ThiTLiraglutide, a long-acting human glucagon-like peptide 1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetesDiabetes Care2007301608161017372153
   PubMed Web of Science ®Google Scholar
• IrieSMatsumuraYZdravkovicMJacobsenLVKageyamaSTolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomised, double-blind, placebo-controlled dose-escalation studyInt J Clin Pharmacol Ther20084627327918541123
   PubMed Web of Science ®Google Scholar
• Liraglutide given positive opinion by EMEA. http://www.novonordisk.com/ Accessed May 7, 2009.
   Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trialLancet200937347348118819705
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKfor the Lead-2 Study GroupEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetesDiabetes Care200932849018931095
   PubMed Web of Science ®Google Scholar
• ZinmanBGerichKBuseJBEfficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)Diabetes Care2009321224123019289857
   PubMed Web of Science ®Google Scholar
• MarreMShawKBrandleMon behalf of the LEAD-1 SU study groupLiraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)Diabet Med20092626827819317822
   PubMed Web of Science ®Google Scholar
• Russell-JonesDMolecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogueMol Cell Endocrinol200929713714019041364
   PubMed Web of Science ®Google Scholar
• HarderHNielsenLTuDTAstrupAThe effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetesDiabetes Care2004271915192115277417
   PubMed Web of Science ®Google Scholar
• VilsbollTBrockBPerrildHLiraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stmulated insulin secretion during hyperglycaemia in patients with type 2 diabetesDiabet Med20082515215618201212
   PubMed Web of Science ®Google Scholar
• HorowitzMVilsbøllTZdravkovicMHammerMMadsbadSPatient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutideDiab Obes Metab200810593602
   PubMed Web of Science ®Google Scholar
• FinemanMSShenLZTaylorKKimDDBaronADEffectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesDiabetes Metab Res Rev20042041141715343588
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGThe LEAD-6 Study GroupLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet2009374394719515413
   PubMed Web of Science ®Google Scholar
• BushMAMatthewsJEDe BoeverEHSafety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjectsDiab Obes Metab200911498505
   PubMed Web of Science ®Google Scholar
• MatthewsJEStewartMWDe BoeverEHPharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-activ glucagon-like peptide-1 mimetic, in patients with type 2 diabetesJ Clin Endocrinol Metab2008934810481718812476
   PubMed Web of Science ®Google Scholar
• NauckMARatnerREKapitzaCBerriaRBoldrinMBalenaRTreatment with the human once-weekly GLP-1 analogue taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled with metformin alone: a double-blind placebo-controlled studyDiabetes Care2009321237124319366970
   PubMed Web of Science ®Google Scholar
• DeaconCFHughesTEHolstJJDipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pigDiabetes1998477647699588448
   PubMed Web of Science ®Google Scholar
• MarguetDBaggioLKobayashiTEnhanced insulin secretion and improved glucose tolerance in mice lacking CD26Proc Natl Acad Sci U S A2000976874687910823914
   PubMed Web of Science ®Google Scholar
• ÅhrenBLandin-OlssonMJansenPAInhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetesJ Clin Endocrinol Metab2004892078208415126524
   PubMed Web of Science ®Google Scholar
• HermanGAStevensCVan DyckKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther20057867568816338283
   PubMed Web of Science ®Google Scholar
• MariASallasWMHeYLVildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetesJ Clin Endocrinol Metab2005904888489415886245
   PubMed Web of Science ®Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKLerchCEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesVasc Health Risk Man20084753768
   PubMedGoogle Scholar
• Januvia Summary of Product Characteristics Merck Sharp and Dohme Ltd. www.medicines.org.uk Accessed January 31, 2009.
   Google Scholar
• RazIHanefeldMXuLEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetesDiabetologia2006492564257117001471
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJWuMMeinitngerGEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care2006292638264317130197
   PubMed Web of Science ®Google Scholar
• GoldsteinBFeinglosMNLuncefordJKJohnsonKWilliams-HermanDEEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care2007301979198717485570
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazagRAndryukPJLuKSteinPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20061556156817157112
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMLuoEFanurikDKhatamiHSteinPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab2007973374517593236
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDTerranellaLSteinPPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized double-blind, non-inferiority trialDiabetes Obes Metab2007919420517300595
   PubMed Web of Science ®Google Scholar
• MigoyaEMMillerJLarsonPSitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrationsDiabetes200756A74
   Web of Science ®Google Scholar
• BergmanAJCoteJYiBEffect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitorDiabetes Care2007301862186417468348
   PubMed Web of Science ®Google Scholar
• Galvus® Summary of Product CharacteristicsNovartis Pte Ltd. http://emc.medicines.org.uk/ Accessed February 28, 2009.
   Google Scholar
• Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract20077613213817223217
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care20073021722317259484
   PubMed Web of Science ®Google Scholar
• AhrenBGomisRStandlEtwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care2004272874288015562200
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCRochotteEGarberAJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care20073089089517277036
   PubMed Web of Science ®Google Scholar
• GarberAJSchweizerABaronMARochotteEDejagerSVildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab2007916617417300592
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRPEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitzone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab2007917518517300593
   PubMed Web of Science ®Google Scholar
• D’AlessioDADenneyAMHermillerLMTreatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetesJ Clin Endocrinol Metab200994818818957505
   PubMed Web of Science ®Google Scholar
• MariAScherbaumWANilssonPMCharacterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemiaJ Clin Endocrinol Metab20089310310917925336
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDThe effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover studyClin Endocrinol (Oxf)20086973774418331607
   PubMed Web of Science ®Google Scholar
• ChanJCScottRArjona FerreiraJCSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab20081054555518518892
   PubMed Web of Science ®Google Scholar
• CovingtonPChristopherRDavenportMPharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesClin Ther20083099512
   Web of Science ®Google Scholar
• DeFronzoRAFleckPRWilsonCAMekkiQAlogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyDiabetes Care2008312315231718809631
   PubMed Web of Science ®Google Scholar
• NauckMAEllisGCFleckPRWilsonCAMekkiQAlogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled studyInt J Clin Pract200963465519125992
   PubMed Web of Science ®Google Scholar
• PratleyREKipnesMSFleckPRWilsonCMekkiQAlogliptin Study 007 GroupDiabetes Obes Metab20091116717619125778
   PubMed Web of Science ®Google Scholar
• MoritohYTakeuchiKAsakawaTKataokaOOdakaHCombining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db miceBr J Pharmacol200915741542619371350
   PubMed Web of Science ®Google Scholar
• PratleyJEAlogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesExpert Opin Pharmacother20091050351219191685
   PubMed Web of Science ®Google Scholar
• RosenstockJSankohSListJFGlucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetesDiabetes Obes Metab20081037638818355324
   PubMed Web of Science ®Google Scholar
• DeFronzoRAHissaMBlauwetMBChenRSSaxagliptin added to metformin improves glycemic control in patients with type 2 diabetes [abstract]Diabetes200756Suppl 1A74
   Google Scholar
• RavichandranSChacraARTanGHApanovitchAMChenRSaxagliptin added to a sub-maximal dose sulfonylurea is safe and more efficacious than up-titrating a sulfonylurea in patients with type 2 diabetes [abstract]Diabetologia200851Suppl 1S342
   Google Scholar
• HollanderPAllenELiJChenRSaxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes [abstract]Diabetologia200851Suppl 1S342
   Google Scholar
• DeaconCFHolstJJSaxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesAdv Ther20092648849919444391
   PubMed Web of Science ®Google Scholar
• ViswanathanPChaudhuriABhatiaRExenatide therapy in obese patients with type 2 diabetes mellitus treated with insulinEndocr Pract20071344445017872344
   PubMedGoogle Scholar
• RatnerREMaggsDNielsenLLLong-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitusDiabetes Obes Metab2006841942816776749
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin20082427528618053320
   PubMed Web of Science ®Google Scholar
• SonneDPEngstromTTreimanMProtective effects of GLP-1 analogues exendin-4 and GLP-1 (9–36) amide against ischemia-reperfusion injury in rat heartRegul Pept200814624324917976835
   PubMed Web of Science ®Google Scholar
• Noyan-AshrafMHBanKSadiAThe GLP-1R agonist liraglutide protects cardeomyocytes and improved survival and cardiac function after experimental murine infarction [abstract 190-OR]Presented at the 68th Scientific Sessions of the American Diabetes AssociationSan Francisco, CA66–102008
   Google Scholar
• CourregesJPVilsbollTZdravkovicMBeneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetesDiabet Med2008251129113119183322
   PubMed Web of Science ®Google Scholar
• MistryGCMaesALLasseterKCEffect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertensionJ Clin Pharmacol20084859259818353996
   PubMed Web of Science ®Google Scholar
• ScottRWuMSanchezMEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetesInt J Clin Pract20076117118017156104
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteEEfficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab200810829018034842
   PubMed Web of Science ®Google Scholar
• MatikainenNMänttäriSSchweizerAVildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesDiabetologia2006492049205716816950
   PubMed Web of Science ®Google Scholar
• BoschmannMEngeliSDobbersteinKDipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patientsJ Clin Endocrinol Metab20099484685219088168
   PubMed Web of Science ®Google Scholar
• JonesKLRussoABerryMKA longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitusAm J Med200211344945512427492
   PubMed Web of Science ®Google Scholar
• Delgado-ArosSVellaACamilleriMEffects of glucagon-like peptide 1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunctionNeurogastroenterol Motil20071543544312846732
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Information for Healthcare Professionals Exenatide (marketed as Byetta)www.fda.gov/cder/drug/InfoSheets/HCP/exenatideHCP.htm Accessed August 3, 2009.
   Google Scholar
• NoelRABraunDKPattersonREBloomgrenGIncreased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort studyDiabetes Care20093283483819208917
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b-2-02-NovoNordisk.pdf8995Accessed May 8, 2009
   Google Scholar
• KoehlerJABaggioLLLamontBJAliSDruckerDJGLP-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in miceDiabetes200969[Epub ahead of print]
   Web of Science ®Google Scholar
• MatveyenkoAVDrySCoxHIBeneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metforminDiabetes2009581604161519403868
   PubMed Web of Science ®Google Scholar
• KiefferTJMcIntoshCHPedersonRADegradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology1995136358535967628397
   PubMed Web of Science ®Google Scholar
• De MeesterILambeirAMProostPDipeptidyl peptidase IV substrates: an update on in vitro peptide hydrolysis by human DPPIVAdv Exp Med Biol200352431712675218
   PubMed Web of Science ®Google Scholar
• BussoNWagtmannNHerlingCCirculating CD26 is negatively associated with inflammation in human and experimental arthritisAm J Pathol200516643344215681827
   PubMed Web of Science ®Google Scholar
• MinshallMEOglesbyAKWintleMEEstimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetesValue Health200811223318237357
   PubMed Web of Science ®Google Scholar
• RayJABoyeKSYurginNExenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesCurr Med Res Opin20072360962217355742
   PubMed Web of Science ®Google Scholar
• WoehlAEvansMTetlowAPMcEwanPEvaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United KingdomCardiovasc Diabetol200872418694484
   PubMed Web of Science ®Google Scholar
• BoyeKSMatzaLSOglesbyAPatient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetesHealth Qual Life Outcomes200648017034640
   PubMed Web of Science ®Google Scholar
• SchwarzBGouveiaMChenJCost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapyDiab Obes Metab2008104355
   PubMed Web of Science ®Google Scholar
• ScottRLoeysTDaviesMJEngelSSEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetesDiabetes Obes Metab20081095996918201203
   PubMed Web of Science ®Google Scholar
• LageMJFabunmiRBoyeKSMisurskiDAComparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapyAdv Ther20092621722919219409
   PubMed Web of Science ®Google Scholar
• JellingerPSDavidsonJABlondeLRoad maps to achieve glycemic control n type 2 diabetes mellitusEndocr Pract200713261268
   Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetes Care200831111
   Web of Science ®Google Scholar
• NauckMAWalbergJVethackeABlood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1Regul Pept2004118899714759561
   PubMedGoogle Scholar
• MeierJJWeyheDMichaelyMIntravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetesCrit Care Med20043284885115090972
   PubMed Web of Science ®Google Scholar
• DeaneAMChapmanMJFraserRJBurgstadCBesankoLKHorowitzMThe effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo controlled cross over studyCrit Care200913R67(Epub May 14)19439067
   PubMed Web of Science ®Google Scholar
• NICE-SUGAR Study InvestigatorsFinferSChittockDRSuSYIntensive versus conventional glucose control in critically ill patientsN Engl J Med20093601283129719318384
   PubMed Web of Science ®Google Scholar
• AscheCVMcAdam-MarxCShane-McWhorterLEvaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysisDrugs Aging20082561162218582148
   PubMed Web of Science ®Google Scholar
• HanefeldMHermanGAWuMOnce-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurr Med Res Opin2007231329133917559733
   PubMed Web of Science ®Google Scholar
• PratleyRERosenstockJPi-SunyerFXManagement of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapyDiabetes Care2007303017302217878242
   PubMed Web of Science ®Google Scholar
• MigoyaEMStevensCHBergmanAJEffect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptinCan J Clin Pharmacol200916e165e17019221403
   PubMedGoogle Scholar
• ChanJCScottRArjona FerreiraJCSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab20081054555518518892
   PubMed Web of Science ®Google Scholar